C
CRISPR Therapeutics AG (CRSP)
NGM – Real Time Price. Currency in USD
52.83
-1.18 (-2.18%)
At close: May 12, 2026, 4:00 PM EDT
52.40
-0.43 (-0.81%)
After-hours: May 12, 2026, 7:54 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
52.83
-1.18 (-2.18%)
At close: May 12, 2026, 4:00 PM EDT
52.40
-0.43 (-0.81%)
After-hours: May 12, 2026, 7:54 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 17.96 | 6.05 | 10 | |
| Quick ratio | 17.96 | 5.63 | 10 | |
| Debt to Equity | 0.43 | 0.30 | 7.0 | |
| Debt to Assets | 0.29 | 1.04 | 7.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 1M | 371M | 37M | 4M | 4M |
| Gross Profit | -133M | 221M | -92M | -229M | -217M |
| Operating Income | -673M | -223M | -467M | -568M | -550M |
| Net Income | -650M | -154M | -366M | -582M | -569M |
| EBITDA | -649M | -203M | -447M | -549M | -531M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 697.54 | 51.34 | 10 |
| Next quarter | 1553.59 | 0.44 | 6.0 |
| Current year | 1182.24 | 25.26 | 10 |
| Next year | 205.93 | 20.98 | 10 |
| Weighted average score | 9.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 68.75 | 5.88 | 6.57 | -17.54 | 5.3 |
| Y/Y | 68.55 | 9.61 | 18.99 | -102.01 | 6.5 |
| 3y average | 10234.99 | -40.27 | -31.98 | -14.44 | 3.3 |
| 5y average | 31552.01 | -36.94 | -36.99 | 3.65 | 4.0 |
| Weighted average score | 4.8 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $787.6M significantly exceeds cash reserves ($423.7M), raising financial stability concerns
Total current assets $2.4B exceed Total current liabilities $136.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.4) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$109.4M limits the company's ability to reinvest or pay down debt